Our data also provide a plausible mechanism to explain the link between inflammation and the development of lymphomagenic mutations; especially in DLBCL with a high BCR.1, chronic inflammation and/or chronic antigen driven activation of oncogenic pathways with no or low c-Myc activity. The gene discussed is BCR; the disease is diffuse large B-cell lymphoma.